- Home
- TZUP vs PRLD Comparison
TZUP vs PRLD Comparison
Compare TZUP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZUP
- PRLD
- Stock Information
- Founded
- TZUP 2020
- PRLD 2016
- Country
- TZUP United States
- PRLD United States
- Employees
- TZUP N/A
- PRLD N/A
- Industry
- TZUP
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- TZUP
- PRLD Health Care
- Exchange
- TZUP NYSE
- PRLD Nasdaq
- Market Cap
- TZUP 48.0M
- PRLD 50.1M
- IPO Year
- TZUP N/A
- PRLD 2020
- Fundamental
- Price
- TZUP $7.10
- PRLD $0.88
- Analyst Decision
- TZUP
- PRLD Strong Buy
- Analyst Count
- TZUP 0
- PRLD 2
- Target Price
- TZUP N/A
- PRLD $4.50
- AVG Volume (30 Days)
- TZUP 123.6K
- PRLD 168.1K
- Earning Date
- TZUP 08-11-2025
- PRLD 08-11-2025
- Dividend Yield
- TZUP N/A
- PRLD N/A
- EPS Growth
- TZUP N/A
- PRLD N/A
- EPS
- TZUP N/A
- PRLD N/A
- Revenue
- TZUP $487.00
- PRLD $7,000,000.00
- Revenue This Year
- TZUP N/A
- PRLD N/A
- Revenue Next Year
- TZUP N/A
- PRLD N/A
- P/E Ratio
- TZUP N/A
- PRLD N/A
- Revenue Growth
- TZUP N/A
- PRLD N/A
- 52 Week Low
- TZUP $2.02
- PRLD $0.61
- 52 Week High
- TZUP $9.74
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- TZUP N/A
- PRLD 48.33
- Support Level
- TZUP N/A
- PRLD $0.85
- Resistance Level
- TZUP N/A
- PRLD $1.25
- Average True Range (ATR)
- TZUP 0.00
- PRLD 0.10
- MACD
- TZUP 0.00
- PRLD -0.02
- Stochastic Oscillator
- TZUP 0.00
- PRLD 18.52
About TZUP THUMZUP MEDIA CORP
Thumzup Media Corp operates in the social media branding and marketing industry. The company operates in a single business segment which is social media marketing. The Thumzup App works on both iPhone and Android mobile operating systems and connects brands and people who use and love these brands. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through Venmo and PayPal.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.